Retinal capillary hemodynamics and VEP/pressure tolerance: evidence of retinal microcirculatory compromise in treated glaucomatous eyes.
Measurements of retinal leukocyte velocity were made in single eyes of 6 glaucomatous adults and 9 normal subjects at each of 4 discrete levels of IOP elevation assigned according to the characteristics of prior pattern-evoked cortical potential pressure tolerance measurements. Glaucomatous eyes failed to demonstrate any stabilization in retinal leukocyte velocity at pressures above 45 mm Hg, with velocities 33% lower than normal for a comparable degree of IOP elevation (p < 0.012). Even at baseline IOP, leukocyte velocity was 27.2% slower in the treated glaucomatous eyes than in normal control eyes (p < or = 0.013), despite comparable baseline IOP levels in both groups.
Sponsel
W E
WE
Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, USA.
Zetlan
S R
SR
Stodtmeister
R
R
Kaufman
P L
PL
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005074:Evoked Potentials, Visual / Q000502:physiology*; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy / Q000503:physiopathology*; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D007962:Leukocytes / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D018721:Muscarinic Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D010862:Pilocarpine / Q000008:administration & dosage / Q000627:therapeutic use; D012171:Retinal Vessels / Q000187:drug effects / Q000503:physiopathology*; D013999:Timolol / Q000008:administration & dosage / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D018721:Muscarinic Agonists; D010862:Pilocarpine; D013999:Timolol